Skip navigation

DSpace

機構典藏 DSpace 系統致力於保存各式數位資料(如:文字、圖片、PDF)並使其易於取用。

點此認識 DSpace
DSpace logo
English
中文
  • 瀏覽論文
    • 校院系所
    • 出版年
    • 作者
    • 標題
    • 關鍵字
    • 指導教授
  • 搜尋 TDR
  • 授權 Q&A
    • 我的頁面
    • 接受 E-mail 通知
    • 編輯個人資料
  1. NTU Theses and Dissertations Repository
  2. 公共衛生學院
  3. 流行病學與預防醫學研究所
請用此 Handle URI 來引用此文件: http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/95030
完整後設資料紀錄
DC 欄位值語言
dc.contributor.advisor陳秀熙zh_TW
dc.contributor.advisorHsiu-Hsi Chenen
dc.contributor.author李孟旃zh_TW
dc.contributor.authorMeng-Chang Leeen
dc.date.accessioned2024-08-26T16:20:45Z-
dc.date.available2024-08-27-
dc.date.copyright2024-08-26-
dc.date.issued2024-
dc.date.submitted2024-08-09-
dc.identifier.citation1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS and China Medical Treatment Expert Group for C. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708-1720.
2. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W and Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565-574.
3. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus I and Research T. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382:727-733.
4. Coronavirus disease (COVID-19) pandemic. 2024.
5. WHO COVID-10 dashboard 2024.
6. Summers J, Cheng HY, Lin HH, Barnard LT, Kvalsvig A, Wilson N and Baker MG. Potential lessons from the Taiwan and New Zealand health responses to the COVID-19 pandemic. Lancet Reg Health West Pac. 2020;4:100044.
7. Cheng HY, Chueh YN, Chen CM, Jian SW, Lai SK and Liu DP. Taiwan's COVID-19 response: Timely case detection and quarantine, January to June 2020. J Formos Med Assoc. 2021;120:1400-1404.
8. Chen YH, Cheuh YN, Chen CM and Kuo HW. Epidemiological characteristics of the three waves of COVID-19 epidemic in Taiwan during April 2022 to March 2023. J Formos Med Assoc. 2023;122:1174-1182.
9. Yang CR, Chang SY, Gong YN, Huang CG, Tung TH, Liu W, Chan TC, Hung KS, Shang HS, Tsai JJ, Kao CL, Wu HL, Daisy Liu LY, Lin WY, Fan YC, King CC and Ku CC. The emergence and successful elimination of SARS-CoV-2 dominant strains with increasing epidemic potential in Taiwan's 2021 outbreak. Heliyon. 2023;9:e22436.
10. World Health Organization. Update on omicron. 2021. [Accessed on 6 Jun 2024.] www.who.int/news/item/28-11-2021-update- on-omicron.
11. NCHC COVID-19全球疫情地圖 https://covid-19.nchc.org.tw/2023_city_confirmed.php
12. Castagnoli R, Votto M, Licari A, Brambilla I, Bruno R, Perlini S, Rovida F, Baldanti F and Marseglia GL. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review. JAMA Pediatr. 2020;174:882-889.
13. Chang TH, Wu JL and Chang LY. Clinical characteristics and diagnostic challenges of pediatric COVID-19: A systematic review and meta-analysis. J Formos Med Assoc. 2020;119:982-989.
14. Williams N, Radia T, Harman K, Agrawal P, Cook J and Gupta A. COVID-19 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review of critically unwell children and the association with underlying comorbidities. Eur J Pediatr. 2021;180:689-697.
15. Kompaniyets L, Agathis NT, Nelson JM, Preston LE, Ko JY, Belay B, Pennington AF, Danielson ML, DeSisto CL and Chevinsky JR. Underlying medical conditions associated with severe COVID-19 illness among children. JAMA network open. 2021;4:e2111182-e2111182.
16. Ludvigsson JF. Systematic review of COVID‐19 in children shows milder cases and a better prognosis than adults. Acta paediatrica. 2020;109:1088-1095.
17. Choi JH, Choi S-H and Yun KW. Risk factors for severe COVID-19 in children: a systematic review and meta-analysis. Journal of Korean medical science. 2022;37.
18. 後新冠疫情的兒童多系統發炎症候群(MIS-C)。感染控制雜誌: 中華民國 112 年 4 月第三十三卷二期
19. NCHC COVID-19全球疫情地圖 https://covid-19.nchc.org.tw/2023_city_confirmed.php
20. World Health Organization. News. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern; 2021
[accessed 2024 May 9]https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern
21. 衛生福利部疾病管制局. 新聞稿. 新增94,855例COVID-19確定病例,分別為94,808例本土及47例境外移入; 2022
[accessed 2024 June 1] http://at.cdc.gov.tw/c3Z7JI
22. Siow I, Lee KS, Zhang JJY, Saffari SE and Ng A. Encephalitis as a neurological complication of COVID-19: A systematic review and meta-analysis of incidence, outcomes, and predictors. Eur J Neurol. 2021;28:3491-3502.
23. Scheuermeier M, Chaves KQ, Marin-Sanabria D, Acosta-Lazo H and Ulate-Campos A. First Pediatric Case of Autoimmune Encephalitis Associated With COVID-19 in Costa Rica. Cureus. 2022;14:e30616.
24. Urso L, Distefano MG, Cambula G, Colomba AI, Nuzzo D, Picone P, Giacomazza D and Sicurella L. The case of encephalitis in a COVID-19 pediatric patient. Neurol Sci. 2022;43:105-112.
25. Gaughan M, Connolly S, O'Riordan S, Tubridy N, McGuigan C and Kinsella JA. Pediatric Parainfectious Encephalitis Associated With COVID-19. Neurology. 2021;96:541-544.
26. Wang L, Berger NA, Kaelber DC, Davis PB, Volkow ND and Xu R. COVID infection severity in children under 5 years old before and after Omicron emergence in the US. medRxiv. 2022.
27. Wang L, Berger NA, Kaelber DC, Davis PB, Volkow ND and Xu R. Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron. medRxiv. 2022.
28. Zhu Y, Almeida FJ, Baillie JK, Bowen AC, Britton PN, Brizuela ME, Buonsenso D, Burgner D, Chew KY, Chokephaibulkit K, Cohen C, Cormier SA, Crawford N, Curtis N, Farias CGA, Gilks CF, von Gottberg A, Hamer D, Jarovsky D, Jassat W, Jesus AR, Kemp LS, Khumcha B, McCallum G, Miller JE, Morello R, Munro APS, Openshaw PJM, Padmanabhan S, Phongsamart W, Reubenson G, Ritz N, Rodrigues F, Rungmaitree S, Russell F, Safadi MAP, Saner C, Semple MG, Prado da Silva DGB, de Sousa LMM, Diogo Moco Souza M, Spann K, Walaza S, Wolter N, Xia Y, Yeoh DK, Zar HJ, Zimmermann P, Short KR, International Severe Acute R and Emerging Infection Consortium Comprehensive Clinical Characterisation Collaboration investigatorsPediatric Active Enhanced Disease Surveillance Network g. International Pediatric COVID-19 Severity Over the Course of the Pandemic. JAMA Pediatr. 2023;177:1073-1084.
29. Tso WWY, Kwan MYW, Wang YL, Leung LK, Leung D, Chua GT, Ip P, Fong DYT, Wong WHS, Chan SHS, Chan JFW, Peiris M, Lau YL and Rosa Duque JS. Severity of SARS-CoV-2 Omicron BA.2 infection in unvaccinated hospitalized children: comparison to influenza and parainfluenza infections. Emerg Microbes Infect. 2022;11:1742-1750.
30. 中央通訊社(2022/4/16): 新北2歲童染疫釀腦炎、器官異常 兒童重症首例 https://www.cna.com.tw/news/ahel/202204160099.aspx
31. 111年衛生福利部新聞 4月新聞https://www.mohw.gov.tw/cp-5267-69215-1.html#:~:text=%E4%B8%80%E3%80%81%E8%8B%A5%E5%85%92%E7%AB%A5%E5%87%BA%E7%8F%BE%E4%BB%A5%E4%B8%8B,%E9%80%B2%E9%A3%9F%E6%88%96%E6%9C%AA%E8%A7%A3%E5%B0%BF%E3%80%82
32. Huang SM, Wu CH, Yen TY, Wu ET, Wang CC, Lu FL, Lu CY, Chen JM, Lee PI, Lee WT, Chang LY and Huang LM. Clinical characteristics and factors associated with severe COVID-19 in hospitalized children during the SARS-CoV-2 Omicron pandemic in Taiwan. J Microbiol Immunol Infect. 2023;56:961-969.
33. Cheng CY, Tsai CH, Wang HP, Chiu WT, Hung HC, Chi CY and Tsai IJ. Successful treatment of acute encephalitis and hepatitis in a child with COVID-19 infection. J Formos Med Assoc. 2023;122:182-186.
34. Hon KL, Tan YW, Leung K, Cheung WL, Hui WF, Chung FS and Torres A. Pediatric COVID-19 acute encephalopathy and mortality. Curr Pediatr Rev. 2022.
35. Li L, Liao H, Kuang X and Jin K. Clinical characteristics and outcomes of COVID-19-associated encephalopathy in children. J Neurovirol. 2024.
36. 疾病管制署致醫界通函第481號(2022/05/26)https://www.cdc.gov.tw/Bulletin/Detail/Ij__ijhgFKEqeJwK7nJsbA?typeid=48
37. Chu YJ, Wong LC, Ho CS, Huang JY, Lee IC, Wang HP, Huang CH, Hsu CJ, Hsu WH, Kao YC, Duan BC, Lee IC, Kuo YT, Chang FM, Hu SC, Wu CC, Lin LC, Hsiao WL, Wang CY, Hung KL, Chi HJ, Wong SB and Lee WT. Neurological manifestations of SARS-CoV-2 infection in children in Taiwan: A cross-section, multicenter study. J Formos Med Assoc. 2024.
38. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N and Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395:1607-1608.
39. Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, Bonanomi E and D'Antiga L. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. The Lancet. 2020;395:1771-1778.
40. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, Newburger JW, Kleinman LC, Heidemann SM and Martin AA. Multisystem inflammatory syndrome in US children and adolescents. New England Journal of Medicine. 2020;383:334-346.
41. World Health Organization Scientific Brief. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19. Available from: https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19. Accessed April 17, 2024
42. Centers of Disease Control and Prevention. Information for Healthcare Providers about Multisystem Inflammatory Syndrome in Children (MIS-C). Available from: https://www.cdc.gov/mis/mis-c/hcp_cstecdc/index.html. Accessed April 17, 2024
43. 後新冠疫情的兒童多系統發炎症候群(MIS-C)。感染控制雜誌。中華民國 112 年 4 月第三十三卷二期
44. Tseng CT, Lin JJ, Huang JL, Chiu CH and Wu CY. Clinical manifestations and outcomes associated with PICU admission in children with multisystem inflammatory syndrome in Taiwan: A retrospective cohort study. International Journal of Rheumatic Diseases. 2024;27:e14970.
45. Wu CH, Chang TH, Tan BF, Wu JL, Huang SM, Yen TY, Wu ET, Wang CC, Lin MT, Lu CY, Chang LY and Huang LM. Clinical manifestations and risk factors of shock in children with multisystem inflammatory syndrome. J Formos Med Assoc. 2024;123:496-500.
46. 內政部戶政司全球資訊網: 人口統計資料https://www.ris.gov.tw/app/portal/346
47. Huang PC, Lin TY, Chen CC, Wang SW, Tsai BY, Tsai PJ, Tu YF, Ko WC, Cheng CM, Shieh CC, Liu CC, Shen CF and Taiwan Pediatric Infectious Disease A. Age and prior vaccination determine the antibody level in children with primary SARS-CoV-2 Omicron infection. J Microbiol Immunol Infect. 2023;56:1187-1197.
48. Wang L, Berger NA, Kaelber DC, Davis PB, Volkow ND and Xu R. Incidence Rates and Clinical Outcomes of SARS-CoV-2 Infection With the Omicron and Delta Variants in Children Younger Than 5 Years in the US. JAMA Pediatrics. 2022;176:811-813.
49. 淺談新冠肺炎病毒 Omicron 變異株對兒童族群的影響。感染控制雜誌: 中華民國 111 年 8 月第三十二卷四期
50. Cloete J, Kruger A, Masha M, du Plessis NM, Mawela D, Tshukudu M, Manyane T, Komane L, Venter M and Jassat W. Paediatric hospitalisations due to COVID-19 during the first SARS-CoV-2 omicron (B. 1.1. 529) variant wave in South Africa: a multicentre observational study. The Lancet Child & Adolescent Health. 2022;6:294-302.
51. Chen YH, Lee CY, Cheng HY, Chen CM, Cheuh YN, Lee CL and Kuo HW. Risk factors and mortality of SARS-CoV-2 reinfection during the Omicron era in Taiwan: A nationwide population-based cohort study. J Microbiol Immunol Infect. 2024;57:30-37.
52. Bahl A, Mielke N, Johnson S, Desai A and Qu L. Severe COVID-19 outcomes in pediatrics: An observational cohort analysis comparing Alpha, Delta, and Omicron variants. Lancet Reg Health Am. 2023;18:100405.
53. Butt AA, Dargham SR, Loka S, Shaik RM, Chemaitelly H, Tang P, Hasan MR, Coyle PV, Yassine HM, Al-Khatib HA, Smatti MK, Kaleeckal AH, Latif AN, Zaqout A, Almaslamani MA, Al Khal A, Bertollini R, Abou-Samra AB and Abu-Raddad LJ. Coronavirus Disease 2019 Disease Severity in Children Infected With the Omicron Variant Clinical Infectious Diseases. 2022;75:e361-e367.
54. Misra S, Kolappa K, Prasad M, Radhakrishnan D, Thakur KT, Solomon T, Michael BD, Winkler AS, Beghi E, Guekht A, Pardo CA, Wood GK, Hsiang-Yi Chou S, Fink EL, Schmutzhard E, Kheradmand A, Hoo FK, Kumar A, Das A, Srivastava AK, Agarwal A, Dua T and Prasad K. Frequency of Neurologic Manifestations in COVID-19: A Systematic Review and Meta-analysis. Neurology. 2021;97:e2269-e2281.
55. Ludvigsson JF. Convulsions in children with COVID-19 during the Omicron wave. Acta Paediatr. 2022;111:1023-1026.
56. Murata Y, Tomari K and Matsuoka T. Children with croup and SARS-CoV-2 infection during the large outbreak of Omicron. The Pediatric infectious disease journal. 2022;41:e249.
57. Tunҫ EM, Shin CKJ, Usoro E, Thomas-Smith SE, Migita RT, Trehan I and Keilman AE. Pediatric croup during the COVID-19 omicron variant surge. medRxiv. 2022:2022.02. 02.22270222.
58. Ludvigsson JF. Convulsions in children with COVID‐19 during the Omicron wave. Acta Paediatrica. 2022;111:1023-1026.
59. Joung J, Yang H, Choi YJ, Lee J and Ko Y. The impact of Omicron wave on pediatric febrile seizure. Journal of Korean Medical Science. 2023;38.
60. Abrams JY, Oster ME, Godfred-Cato SE, Bryant B, Datta SD, Campbell AP, Leung JW, Tsang CA, Pierce TJ and Kennedy JL. Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study. The Lancet Child & Adolescent Health. 2021;5:323-331.
61. Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, Soma VL, Maddux AB, Mourani PM, Bowens C, Maamari M, Hall MW, Riggs BJ, Giuliano JS, Jr, Singh AR, Li S, Kong M, Schuster JE, McLaughlin GE, Schwartz SP, Walker TC, Loftis LL, Hobbs CV, Halasa NB, Doymaz S, Babbitt CJ, Hume JR, Gertz SJ, Irby K, Clouser KN, Cvijanovich NZ, Bradford TT, Smith LS, Heidemann SM, Zackai SP, Wellnitz K, Nofziger RA, Horwitz SM, Carroll RW, Rowan CM, Tarquinio KM, Mack EH, Fitzgerald JC, Coates BM, Jackson AM, Young CC, Son MBF, Patel MM, Newburger JW, Randolph AG and Investigators OC-. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. JAMA. 2021;325:1074-1087.
62. Fleming-Dutra KE, Britton A, Shang N, Derado G, Link-Gelles R, Accorsi EK, Smith ZR, Miller J, Verani JR and Schrag SJ. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance. JAMA. 2022;327:2210-2219.
63. Price AM, Olson SM, Newhams MM, Halasa NB, Boom JA, Sahni LC, Pannaraj PS, Irby K, Bline KE, Maddux AB, Nofziger RA, Cameron MA, Walker TC, Schwartz SP, Mack EH, Smallcomb L, Schuster JE, Hobbs CV, Kamidani S, Tarquinio KM, Bradford TT, Levy ER, Chiotos K, Bhumbra SS, Cvijanovich NZ, Heidemann SM, Cullimore ML, Gertz SJ, Coates BM, Staat MA, Zinter MS, Kong M, Chatani BM, Hume JR, Typpo KV, Maamari M, Flori HR, Tenforde MW, Zambrano LD, Campbell AP, Patel MM, Randolph AG and Overcoming Covid I. BNT162b2 Protection against the Omicron Variant in Children and Adolescents. N Engl J Med. 2022;386:1899-1909.
64. Cohen-Stavi CJ, Magen O, Barda N, Yaron S, Peretz A, Netzer D, Giaquinto C, Judd A, Leibovici L, Hernan MA, Lipsitch M, Reis BY, Balicer RD and Dagan N. BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age. N Engl J Med. 2022;387:227-236.
65. Yung CF, Pang D, Kam KQ, Lye DC, Ong B, Chong CY and Tan KB. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study. Lancet Child Adolesc Health. 2023;7:463-470.
66. Berg SK, Wallach-Kildemoes H, Rasmussen LR, Nygaard U, Bundgaard H, Ersboll AK, Bering L, Thygesen LC, Nielsen SD and Christensen AV. The Impact of Vaccination against SARS-CoV-2 on Health Outcomes and Hospital Visits after Omicron Infection in Children and Adolescents Aged 5-18 Years: A Danish Nation-Wide Cohort Study. Vaccines (Basel). 2023;11.
67. Khan FL, Nguyen JL, Singh TG, Puzniak LA, Wiemken TL, Schrecker JP, Taitel MS, Zamparo JM, Jodar L and McLaughlin JM. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age. JAMA Netw Open. 2022;5:e2246915.
68. Buonsenso D, Cusenza F, Passadore L, Bonanno F, De Guido C and Esposito S. Duration of immunity to SARS-CoV-2 in children after natural infection or vaccination in the omicron and pre-omicron era: A systematic review of clinical and immunological studies. Frontiers in immunology. 2023;13:1024924.
69. Katz SE and Edwards K. Protecting Children Against Omicron. JAMA. 2022;327:2195-2197.
70. 衛生福利部疾病管制署. COVID-19疫苗統計資料. Available from: https://www.cdc.gov.tw/File/Get/S-Uk62a81ni6PjqM76051w. Accessed June 19, 2024.
-
dc.identifier.urihttp://tdr.lib.ntu.edu.tw/jspui/handle/123456789/95030-
dc.description.abstract研究目的
2022年,SARS-CoV-2 Omicron變異株在台灣兒童中引發大規模COVID-19感染高峰。然而,兒童首次感染Omicron變異株的特徵、流行病學,以及中重症的發生情況尚未明確。本研究分析彰化全縣兒童確診資料,以了解兒童首次感染SARS-CoV-2 Omicron變異株的特徵和流行病學,並分析兒童COVID-19中重症發生比例及相關危險因子。
研究方法
研究使用彰化縣COVID-19疫情監測資料,進行回顧性分析研究。資料收集自2022年4月起至2023年3月止,期間內所有十八歲以下確診SARS-CoV-2兒童。研究分析確診兒童的人口統計學特徵、感染流行病學數據和疫苗接種狀況,並應用多變量羅吉斯迴歸及貝氏羅吉斯迴歸,分析發生COVID-19中重症與否之相關風險因子。
研究結果
研究期間,彰化縣共有85,702例兒童COVID-19確診案例,其中男性佔52.9%,年齡中位數為10歲(四分位數間距6-14歲)。不同年齡層兒童的感染率在Omicron變異株的不同亞型感染高峰中,具顯著差異:第一波BA.2亞型感染高峰以六個月至四歲的幼兒感染率最高,第二波BA.5亞型感染高峰以十二至十七歲的青少年感染率最高,而第三波BA.2.75亞型感染高峰則各年齡層的累積確診率相對平均。在所有兒童確診案例中,中重症共38例(0.044%),其中包括7例死亡案例。多變量羅吉斯迴歸分析結果顯示,年齡層和疫苗接種劑數為中重症發生的顯著影響因子。年齡較小的兒童更易發展為COVID-19中重症,尤其是零至六個月嬰兒,與十二歲以下其他年齡層相比,得到中重症的概率較高。疫苗接種率以十二至十七歲的青少年最高(83.4%),六個月至四歲幼兒接種率最低(10.0%)。而完成兩劑疫苗接種顯著降低了發展為中重度 COVID-19 的概率,多變量羅吉斯迴歸(調整勝算比為0.14,95%信賴區間0.06-0.35,P值 < 0.001)及貝氏羅吉斯迴歸分析(勝算比為0.05,95%信賴區間0.04-0.06)結果一致,均顯示接種疫苗有顯著保護作用。
結論
在國內Omicron 流行高峰期間,相較成人病患,兒童族群中SARS-CoV-2感染顯著,相較成人病患,兒童的累積確診率更高。愈年幼的兒童愈少完整接種SARS-CoV-2疫苗,而不完全的疫苗接種與發生COVID-19中重症顯著相關。本研究提供一般社區兒童大規模SARS-CoV-2感染之流行病學全貌,提示相關衛生主管單位,應加強重視並普及幼兒族群疫苗接種,確保幼兒得到足夠保護力,避免COVID-19中重症發生。
zh_TW
dc.description.abstractObjective
Native infection of SARS-CoV-2 Omicron variant caused large-scale domestic COVID-19 peaks among Taiwan pediatric population in 2022. However, the characteristics, epidemiology, and incidence of severe COVID-19 of children infected with the Omicron variant for the first time remain unclear. This study analyzes the confirmed cases of children in Changhua County to understand the characteristics and epidemiology of the native Omicron infections in children and to determine the proportion and risk factors associated with severe COVID-19.
Method
This retrospective study used COVID-19 surveillance data from Changhua County. Data were collected from April 2022 to March 2023, including all confirmed SARS-CoV-2 cases in children under 18. The study analyzed demographic characteristics, epidemiological data, and vaccination status of the confirmed cases. Multivariate logistic regression and Bayesian logistic regression were used to identify risk factors associated with severe COVID-19.
Result
During the study period, there were 85,702 confirmed pediatric COVID-19 cases in Changhua County, with male accounting for 52.9% and a median age of 10 years (IQR 6-14 years). The cumulative incidence varied significantly among different age groups during the peaks of different Omicron subvariants: during the first BA.2 subvariant peak, the highest infection rate was among infants aged 6 months to 4 years; highest incidence among adolescents aged 12 to 17 years was found in the second BA.5 subvariant peak; and during the third BA.2.75 subvariant peak, the cumulative incidences were similar between all age groups. There were 38 severe cases (0.044%) among all confirmed pediatric cases, including 7 deaths. Multivariate logistic regression analysis indicated that age group and the number of vaccine doses were significant factors influencing the development of severe COVID-19. Younger children were more likely to develop severe COVID-19, especially infants aged 0 to 6 months, who had a higher probability of severe COVID-19 compared to other age groups under 12. Vaccination rates were highest among adolescents aged 12 to 17 years (83.4%) and lowest among infants aged 6 months to 4 years (10.0%). Completing two doses of vaccine significantly reduced the likelihood of developing severe COVID-19. The results of multivariate logistic regression (OR: 0.14, 95% CI: 0.06-0.35, P < 0.001) and Bayesian logistic regression (OR: 0.05, 95% CI: 0.04-0.06) consistently demonstrated a significant protective effect of vaccination.
Conclusion
SARS-CoV-2 infections were notably prevalent among the pediatric population during domestic Omicron peaks. Younger children tended to receive fewer vaccine doses, and incomplete vaccination was significantly associated with the occurrence of severe COVID-19. This study provides an epidemiological overview of large-scale SARS-CoV-2 infections among children in the general community, highlighting the need for health authorities to focus on and promote vaccination among young children to ensure adequate protection and prevent severe COVID-19 cases.
en
dc.description.provenanceSubmitted by admin ntu (admin@lib.ntu.edu.tw) on 2024-08-26T16:20:45Z
No. of bitstreams: 0
en
dc.description.provenanceMade available in DSpace on 2024-08-26T16:20:45Z (GMT). No. of bitstreams: 0en
dc.description.tableofcontents口試委員會審定書 i
誌謝 ii
中文摘要 iii
英文摘要 v
目次 vii
圖次 x
表次 xi
第一章 緒論 1
1.1研究背景 1
1.2研究目的 2
第二章 文獻回顧 4
2.1台灣COVID-19傳播概況 4
2.1.1Omicron變異株感染之疫情高峰 5
2.2兒童SARS-CoV-2感染 5
2.2.1台灣兒童嚴重COVID-19感染 6
2.3 SARS-CoV-2感染後兒童多系統發炎症候群 (Multisystem Inflammatory Syndrome in Children, MIS-C) 7
2.3.1台灣兒童多系統發炎症候群 7
2.4台灣兒童COVID-19疫苗施打時程及保護效用 8
第三章 研究方法 10
3.1研究設計與架構 10
3.2研究工具 10
3.3研究對象 10
3.3.1資料內容 10
3.3.2中重症定義 10
3.3.3定義完整疫苗接種 11
3.4資料處理及統計方法 11
3.4.1特徵描述分析 11
3.4.2單變量分析 11
3.4.3多變量分析 12
3.4.4貝氏分析 12
第四章 研究結果 16
4.1彰化縣兒童COVID-19感染:流行病學及特徵 16
4.2彰化縣確診兒童SARS-CoV-2疫苗接種 17
4.3彰化縣兒童COVID-19中重症 18
4.3.1COVID-19神經重症及兒童多系統發炎症候群 19
4.4中重症確診兒童之危險因子 20
4.4.1單變量分析 20
4.4.2多變量分析 22
4.5貝氏分析:兒童COVID-19中重症 25
4.5.1疫苗預防兒童COVID-19住院效益貝氏分析 28
第五章 討論 29
5.1彰化縣兒童COVID-19流行病學特徵 29
5.2兒童COVID-19中重症 31
5.3Omicron變異株流行期間之疫苗保護效力 33
5.4台灣各區域兒童COVID-19中重症比較 35
5.5研究貢獻 36
5.6研究限制 36
第六章 結論與建議 37
第七章 參考文獻 38
-
dc.language.isozh_TW-
dc.subject新型冠狀病毒疫苗zh_TW
dc.subject兒童腦炎zh_TW
dc.subject兒童多系統發炎症候群zh_TW
dc.subjectOmicron變異株zh_TW
dc.subject新型冠狀病毒感染zh_TW
dc.subject兒童中重症zh_TW
dc.subjectCOVID-19 vaccinesen
dc.subjectCOVID-19en
dc.subjectSARS-CoV-2en
dc.subjectOmicron varianten
dc.subjectpediatricen
dc.subjectsevere COVID-19en
dc.title台灣某社區兒童COVID-19感染:特徵、流行病學與中重症風險分析zh_TW
dc.titleSARS-CoV-2 Infections among Children in A Community in Taiwan: A Study of Characteristics, Epidemiology, and Risk Analysisen
dc.typeThesis-
dc.date.schoolyear112-2-
dc.description.degree碩士-
dc.contributor.oralexamcommittee陳祈玲;江文莒;嚴明芳;葉彥伯zh_TW
dc.contributor.oralexamcommitteeChi-Ling Chen;Wen-Chu Chiang;Ming-Fang Yen;Yen-Po Yehen
dc.subject.keyword新型冠狀病毒感染,Omicron變異株,兒童中重症,兒童腦炎,兒童多系統發炎症候群,新型冠狀病毒疫苗,zh_TW
dc.subject.keywordCOVID-19,SARS-CoV-2,Omicron variant,pediatric,severe COVID-19,COVID-19 vaccines,en
dc.relation.page44-
dc.identifier.doi10.6342/NTU202404110-
dc.rights.note同意授權(限校園內公開)-
dc.date.accepted2024-08-10-
dc.contributor.author-college公共衛生學院-
dc.contributor.author-dept流行病學與預防醫學研究所-
dc.date.embargo-lift2029-08-09-
顯示於系所單位:流行病學與預防醫學研究所

文件中的檔案:
檔案 大小格式 
ntu-112-2.pdf
  未授權公開取用
1.44 MBAdobe PDF檢視/開啟
顯示文件簡單紀錄


系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。

社群連結
聯絡資訊
10617臺北市大安區羅斯福路四段1號
No.1 Sec.4, Roosevelt Rd., Taipei, Taiwan, R.O.C. 106
Tel: (02)33662353
Email: ntuetds@ntu.edu.tw
意見箱
相關連結
館藏目錄
國內圖書館整合查詢 MetaCat
臺大學術典藏 NTU Scholars
臺大圖書館數位典藏館
本站聲明
© NTU Library All Rights Reserved